Cargando…
232. Do Antibiotic Timeouts Improve Antibiotic Utilization?
BACKGROUND: The antibiotic timeout (ATO) is a stewardship tool that protocolizes review of objective clinical data after a predefined period of time and encourages antimicrobial regimen re-assessment. METHODS: Vizient member hospitals were utilized to recruit a variety of acute healthcare institutio...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255487/ http://dx.doi.org/10.1093/ofid/ofy210.243 |
_version_ | 1783373952150667264 |
---|---|
author | Kinn, Patrick Postelnick, Michael Kuper, Kristi Gibson, Amanda Pakyz, Amy Schulz, Lucas T |
author_facet | Kinn, Patrick Postelnick, Michael Kuper, Kristi Gibson, Amanda Pakyz, Amy Schulz, Lucas T |
author_sort | Kinn, Patrick |
collection | PubMed |
description | BACKGROUND: The antibiotic timeout (ATO) is a stewardship tool that protocolizes review of objective clinical data after a predefined period of time and encourages antimicrobial regimen re-assessment. METHODS: Vizient member hospitals were utilized to recruit a variety of acute healthcare institutions, including institutions with and without an ATO process. Participating institutions submitted de-identified patient-level antibiotic therapy courses from a single day within a 5-week window to create a snapshot of overall antibiotic utilization. Therapy courses were evaluated on metrics including the prevalence of anti-pseudomonal agents, agents active against methicillin-resistant Staphylococcus aureus (MRSA), and oral (vs. intravenous) antibiotics. The outcome measures included: percent changes in prevalence of courses with antipseudomonal and anti-MRSA agents after day 3, and percent change in antibiotics ordered for oral administration after day 3. These outcome measures were compared between ATO institutions and non-ATO institutions. RESULTS: A total of 6,184 antibiotic therapy courses were collected from 61 participating institutions (17 ATO institutions; 44 non-ATO institutions). Of 71 institutions that completed enrollment survey, 10 did not complete submission of therapy course data. Antibiotic courses prescribed for prophylaxis (n = 975) and courses that extended beyond 7 days (n = 1,192) were excluded from analysis, resulting in an analysis group that included 4,017 therapy courses (1,396 from ATO institutions vs. 2,621 from non-ATO institutions). The prevalence of patients receiving anti-pseudomonal agents increased after day 3 by 3.03% (P = 0.28) at ATO institutions and decreased 0.45% (P = 0.84) at non-ATO institutions. The prevalence of patients receiving anti-MRSA agents decreased after day 3 by 2.16% (P = 0.41) at ATO institutions and decreased 5.05% (P = 0.005) at non-ATO institutions. Oral antibiotic use increased after day 3 by 3.09% (P = 0.08) at ATO institutions while use at non-ATO institutions increased 7.99% (P = 0.0001). CONCLUSION: Antibiotic therapy course data collected across multiple sites provided no evidence for improved antimicrobial utilization among institutions that have implemented an antibiotic timeout compared with institutions without a timeout. [Image: see text] DISCLOSURES: All authors: No reported disclosures. |
format | Online Article Text |
id | pubmed-6255487 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-62554872018-11-28 232. Do Antibiotic Timeouts Improve Antibiotic Utilization? Kinn, Patrick Postelnick, Michael Kuper, Kristi Gibson, Amanda Pakyz, Amy Schulz, Lucas T Open Forum Infect Dis Abstracts BACKGROUND: The antibiotic timeout (ATO) is a stewardship tool that protocolizes review of objective clinical data after a predefined period of time and encourages antimicrobial regimen re-assessment. METHODS: Vizient member hospitals were utilized to recruit a variety of acute healthcare institutions, including institutions with and without an ATO process. Participating institutions submitted de-identified patient-level antibiotic therapy courses from a single day within a 5-week window to create a snapshot of overall antibiotic utilization. Therapy courses were evaluated on metrics including the prevalence of anti-pseudomonal agents, agents active against methicillin-resistant Staphylococcus aureus (MRSA), and oral (vs. intravenous) antibiotics. The outcome measures included: percent changes in prevalence of courses with antipseudomonal and anti-MRSA agents after day 3, and percent change in antibiotics ordered for oral administration after day 3. These outcome measures were compared between ATO institutions and non-ATO institutions. RESULTS: A total of 6,184 antibiotic therapy courses were collected from 61 participating institutions (17 ATO institutions; 44 non-ATO institutions). Of 71 institutions that completed enrollment survey, 10 did not complete submission of therapy course data. Antibiotic courses prescribed for prophylaxis (n = 975) and courses that extended beyond 7 days (n = 1,192) were excluded from analysis, resulting in an analysis group that included 4,017 therapy courses (1,396 from ATO institutions vs. 2,621 from non-ATO institutions). The prevalence of patients receiving anti-pseudomonal agents increased after day 3 by 3.03% (P = 0.28) at ATO institutions and decreased 0.45% (P = 0.84) at non-ATO institutions. The prevalence of patients receiving anti-MRSA agents decreased after day 3 by 2.16% (P = 0.41) at ATO institutions and decreased 5.05% (P = 0.005) at non-ATO institutions. Oral antibiotic use increased after day 3 by 3.09% (P = 0.08) at ATO institutions while use at non-ATO institutions increased 7.99% (P = 0.0001). CONCLUSION: Antibiotic therapy course data collected across multiple sites provided no evidence for improved antimicrobial utilization among institutions that have implemented an antibiotic timeout compared with institutions without a timeout. [Image: see text] DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2018-11-26 /pmc/articles/PMC6255487/ http://dx.doi.org/10.1093/ofid/ofy210.243 Text en © The Author(s) 2018. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Abstracts Kinn, Patrick Postelnick, Michael Kuper, Kristi Gibson, Amanda Pakyz, Amy Schulz, Lucas T 232. Do Antibiotic Timeouts Improve Antibiotic Utilization? |
title | 232. Do Antibiotic Timeouts Improve Antibiotic Utilization? |
title_full | 232. Do Antibiotic Timeouts Improve Antibiotic Utilization? |
title_fullStr | 232. Do Antibiotic Timeouts Improve Antibiotic Utilization? |
title_full_unstemmed | 232. Do Antibiotic Timeouts Improve Antibiotic Utilization? |
title_short | 232. Do Antibiotic Timeouts Improve Antibiotic Utilization? |
title_sort | 232. do antibiotic timeouts improve antibiotic utilization? |
topic | Abstracts |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255487/ http://dx.doi.org/10.1093/ofid/ofy210.243 |
work_keys_str_mv | AT kinnpatrick 232doantibiotictimeoutsimproveantibioticutilization AT postelnickmichael 232doantibiotictimeoutsimproveantibioticutilization AT kuperkristi 232doantibiotictimeoutsimproveantibioticutilization AT gibsonamanda 232doantibiotictimeoutsimproveantibioticutilization AT pakyzamy 232doantibiotictimeoutsimproveantibioticutilization AT schulzlucast 232doantibiotictimeoutsimproveantibioticutilization |